New study tests eltrombopag safety in kids with rare bone marrow failure

NCT ID NCT06287268

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is tracking 10 children aged 6 to 17 with aplastic anemia, a condition where the bone marrow stops making enough blood cells. The children are receiving eltrombopag (Revolade) for the first time, combined with anti-thymocyte globulin. Researchers are monitoring for serious side effects and how well the drug works, aiming to confirm its safety and effectiveness in this specific group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: eltrombopag (Revolade)
What this could lead to: If successful, this could confirm that eltrombopag is safe and effective for treating aplastic anemia in children who haven't had prior immune-suppressing therapy.
What could go wrong: This is a small, observational study with only 10 participants, so results may not apply broadly. It is not designed to prove a cure, and risks like serious side effects are being monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aplastic anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

APLASTIC ANEMIA

Contacts and locations

Locations

Novartis Investigative Site
RECRUITING

Nagoya, Aichi-ken, 453-8511, Japan
Novartis Investigative Site
RECRUITING

Nagoya, Aichi-ken, 4668560, Japan
Novartis Investigative Site
RECRUITING

Toyoake, Aichi-ken, 4701192, Japan
Novartis Investigative Site
RECRUITING

Chiba, Chiba, 260 8677, Japan
Novartis Investigative Site
RECRUITING

Amagasaki, Hyōgo, 660 8550, Japan
Novartis Investigative Site
RECRUITING

Kobe, Hyōgo, 6500047, Japan
Novartis Investigative Site
RECRUITING

Matsumoto, Nagano, 3908621, Japan
Novartis Investigative Site
RECRUITING

Shimajiri-Gun, Okinawa, 901-1303, Japan
Novartis Investigative Site
RECRUITING

Izumi, Osaka, 5941101, Japan
Novartis Investigative Site
RECRUITING

Osaka, Osaka, 5340021, Japan
Novartis Investigative Site
RECRUITING

Sakai, Osaka, 590-0197, Japan
Novartis Investigative Site
RECRUITING

Saitama, Saitama, 3308777, Japan
Novartis Investigative Site
RECRUITING

Ohtsu, Shiga, 5202192, Japan
Novartis Investigative Site
RECRUITING

Chuo Ku, Tokyo, 1048560, Japan
Novartis Investigative Site
RECRUITING

Ōta-ku, Tokyo, 143 8541, Japan
Novartis Investigative Site
RECRUITING

Setagaya-ku, Tokyo, 1578535, Japan
Novartis Investigative Site
RECRUITING

Wakayama, Wakayama, 641-8510, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.